# Ethics Document Templates

Templates for IRB/ethics committee submissions.

## Protocol Synopsis Template

```
STUDY PROTOCOL SYNOPSIS

1. STUDY TITLE
[Full descriptive title]

2. PRINCIPAL INVESTIGATOR
Name: [Name]
Department: [Department]
Institution: [Institution]
Contact: [Email/Phone]

3. CO-INVESTIGATORS
[List with affiliations]

4. STUDY OBJECTIVES
Primary Objective:
[State primary objective]

Secondary Objectives:
- [Secondary objective 1]
- [Secondary objective 2]

5. STUDY DESIGN
Type: [RCT/Cohort/Case-Control/Cross-Sectional/Case Series]
Duration: [Enrollment and follow-up periods]
Setting: [Single/Multi-center, location(s)]

6. STUDY POPULATION
Inclusion Criteria:
- [Criterion 1]
- [Criterion 2]
- [Criterion 3]

Exclusion Criteria:
- [Criterion 1]
- [Criterion 2]

7. SAMPLE SIZE
Total: [N]
Justification: [Power calculation or rationale]

8. STUDY PROCEDURES
[Brief description of what participants undergo]

Visit Schedule:
- Baseline: [Procedures]
- Follow-up 1 (Week X): [Procedures]
- Follow-up 2 (Week X): [Procedures]

9. OUTCOME MEASURES
Primary Outcome:
[Description, measurement method, timing]

Secondary Outcomes:
- [Outcome 1]
- [Outcome 2]

10. STATISTICAL ANALYSIS
[Brief analysis plan]

11. RISKS AND BENEFITS
Potential Risks:
- [Risk 1]: [Probability, mitigation]
- [Risk 2]: [Probability, mitigation]

Potential Benefits:
- [Direct benefits to participants]
- [Indirect/societal benefits]

Risk-Benefit Assessment:
[Statement that benefits outweigh risks]

12. DATA MANAGEMENT
[Brief data handling description]

13. ETHICAL CONSIDERATIONS
- Informed consent process
- Confidentiality measures
- Vulnerable populations (if applicable)

14. TIMELINE
[Key milestones and dates]
```

---

## Informed Consent Template

```
INFORMED CONSENT FORM

STUDY TITLE: [Title in lay language]

PRINCIPAL INVESTIGATOR: [Name, Contact]
INSTITUTION: [Name]

You are being invited to participate in a research study. This form 
explains the study so you can decide whether to participate. Please 
read carefully and ask questions about anything you do not understand.

WHY IS THIS STUDY BEING DONE?
[2-3 sentences explaining purpose in simple language]

WHY AM I BEING ASKED TO PARTICIPATE?
[Explain eligibility criteria in simple terms]

HOW MANY PEOPLE WILL PARTICIPATE?
Approximately [N] people will participate in this study.

WHAT WILL HAPPEN IF I PARTICIPATE?
If you agree to participate, you will be asked to:

[List procedures in order, with timing]
1. [Procedure 1] - This takes approximately [time]
2. [Procedure 2] - This takes approximately [time]

The total time commitment is approximately [total time].

[For RCTs: Explain randomization]
You will be randomly assigned (like flipping a coin) to receive 
either [intervention] or [control]. Neither you nor the study 
doctor will choose which group you are in.

WHAT ARE THE RISKS?
The possible risks of participating include:

• [Risk 1] - [Likelihood and description]
• [Risk 2] - [Likelihood and description]

[If minimal risk:]
The risks of this study are no greater than those encountered 
in everyday life.

WHAT ARE THE BENEFITS?
[Direct benefits, if any]
You may or may not benefit directly from participating. 

[Indirect benefits]
The information learned may help future patients with [condition].

WILL I BE PAID?
[Payment details or "There is no payment for participating"]

WHAT ARE THE COSTS?
[Cost details or "There are no costs to you for participating"]

WHAT ABOUT CONFIDENTIALITY?
Your information will be kept confidential. We will:
• Store your information securely
• Use a code number instead of your name
• Only share information with the research team
• Never include your name in any reports

Your information may be reviewed by:
• The research team
• The Institutional Review Board
• [Regulatory agencies if applicable]

IS PARTICIPATION VOLUNTARY?
Yes. Your participation is completely voluntary. You may:
• Choose not to participate
• Leave the study at any time
• Refuse any procedure

Your decision will not affect your medical care or relationship 
with [institution].

WHAT IF I HAVE QUESTIONS?
For questions about the study, contact:
[PI Name]: [Phone] or [Email]

For questions about your rights as a research participant, contact:
[IRB contact information]

CONSENT STATEMENT

I have read this consent form and had my questions answered. 
I voluntarily agree to participate in this study.

_________________________ _____________
Participant Signature      Date

_________________________ _____________
Person Obtaining Consent   Date

[If applicable:]
_________________________ _____________
Witness Signature          Date

You will receive a copy of this signed consent form.
```

---

## Data Management Plan Template

```
DATA MANAGEMENT PLAN

1. DATA COLLECTION
Types of Data:
- [Data type 1]: [Collection method]
- [Data type 2]: [Collection method]

Collection Tools:
- [Paper forms / Electronic / Device]

Quality Control:
- [Validation procedures]
- [Double entry / Range checks]

2. DATA STORAGE
Location:
- Primary: [Secure server/cloud service]
- Backup: [Backup location]

Security Measures:
- Password protection
- Encryption: [Type]
- Access controls: [Who has access]

3. DATA IDENTIFIERS
Direct Identifiers Collected:
- [ ] Name
- [ ] Date of birth
- [ ] Medical record number
- [ ] Contact information

De-identification:
- Participant ID codes will be used
- Key linking IDs to names stored separately
- Key access limited to [who]

4. DATA ACCESS
During Study:
- PI and study team: Full access
- Statistician: De-identified data only
- [Others as applicable]

After Study:
- De-identified data available for [purposes]
- Requests reviewed by [who]

5. DATA SHARING
Plans for sharing:
- [ ] No sharing planned
- [ ] Upon reasonable request
- [ ] Public repository

If sharing:
- Data will be de-identified
- Data use agreement required
- Repository: [Name if applicable]

6. DATA RETENTION
Retention Period: [X years] after study completion

Justification: [Regulatory requirements, journal policies]

Destruction Method:
- Electronic: Secure deletion
- Paper: Shredding

7. REGULATORY COMPLIANCE
Applicable Regulations:
- [ ] HIPAA (US)
- [ ] GDPR (EU)
- [ ] [Other local regulations]

Compliance Measures:
- [Specific measures taken]
```

---

## Risk Assessment Categories

### Minimal Risk Studies
- Survey/questionnaire only
- Non-invasive measurements
- Review of existing records

Standard language:
"The risks associated with this study are no greater than those 
encountered in daily life or during routine medical examinations."

### Greater Than Minimal Risk
- Drug/device interventions
- Invasive procedures
- Vulnerable populations

Requires:
- Detailed risk description
- Mitigation strategies
- Data safety monitoring (if applicable)
- Stopping rules

---

## Vulnerable Populations Considerations

### Children/Minors
- Parental/guardian consent
- Age-appropriate assent
- Additional protections

### Pregnant Women
- Risk to fetus assessment
- Partner consent considerations

### Prisoners
- Additional IRB review
- No undue inducement

### Cognitively Impaired
- Capacity assessment
- Legally authorized representative
- Assent when possible

---

## Common IRB Questions

**Q: How will confidentiality be maintained?**
Describe: data coding, secure storage, access limitations, 
reporting without identifiers.

**Q: What are the risks and how are they minimized?**
List each risk with probability and mitigation strategy.

**Q: How will informed consent be obtained?**
Describe: who obtains, setting, opportunity for questions,
documentation.

**Q: Is there potential for coercion?**
Address: voluntary nature, no penalty for refusal, 
power dynamics.

**Q: How is the research team qualified?**
List: relevant training, certifications, experience.
